DK2016089T3 - Gendefekter og mutant-alk-kinase i humane faste tumorer - Google Patents

Gendefekter og mutant-alk-kinase i humane faste tumorer

Info

Publication number
DK2016089T3
DK2016089T3 DK07775495.0T DK07775495T DK2016089T3 DK 2016089 T3 DK2016089 T3 DK 2016089T3 DK 07775495 T DK07775495 T DK 07775495T DK 2016089 T3 DK2016089 T3 DK 2016089T3
Authority
DK
Denmark
Prior art keywords
alk
mutant
kinase
gene defects
human fixed
Prior art date
Application number
DK07775495.0T
Other languages
English (en)
Inventor
Klarisa Rikova
Herbert Haack
Laura Sullivan
Ting-Lei Gu
Ailan Guo
Joan Macneil
Jian Yu
Anthony Possemato
Original Assignee
Cell Signaling Technology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Signaling Technology Inc filed Critical Cell Signaling Technology Inc
Application granted granted Critical
Publication of DK2016089T3 publication Critical patent/DK2016089T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
DK07775495.0T 2006-04-14 2007-04-13 Gendefekter og mutant-alk-kinase i humane faste tumorer DK2016089T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79236406P 2006-04-14 2006-04-14
PCT/US2007/009273 WO2008127248A1 (en) 2007-04-13 2007-04-13 Gene defects and mutant alk kinase in human solid tumors

Publications (1)

Publication Number Publication Date
DK2016089T3 true DK2016089T3 (da) 2014-04-22

Family

ID=39864195

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07775495.0T DK2016089T3 (da) 2006-04-14 2007-04-13 Gendefekter og mutant-alk-kinase i humane faste tumorer

Country Status (10)

Country Link
EP (1) EP2016089B1 (da)
JP (1) JP5562640B2 (da)
KR (3) KR101362284B1 (da)
CN (2) CN112057625A (da)
AU (1) AU2007351581B2 (da)
CA (2) CA2648864C (da)
DK (1) DK2016089T3 (da)
ES (1) ES2458497T3 (da)
HK (1) HK1122040A1 (da)
WO (1) WO2008127248A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120208824A1 (en) * 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
EP2447360A1 (en) 2006-04-14 2012-05-02 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
CA2598893C (en) 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
TWI389893B (zh) 2007-07-06 2013-03-21 Astellas Pharma Inc 二（芳胺基）芳基化合物
US20110110923A1 (en) * 2008-02-12 2011-05-12 The Brigham And Women's Hospital, Inc. Fish assay for eml4 and alk fusion in lung cancer
ES2700098T3 (es) * 2009-05-15 2019-02-14 Insight Genetics Inc Métodos relacionados con las fusiones de ALK para diagnosticar el cáncer
TWI518325B (zh) * 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
US9157905B2 (en) 2010-02-22 2015-10-13 Fujirebio Inc. Method for identifying oncogene, method for establishing oncogene-expressing cell, and method of screening oncogene targeting drug
CN101955995B (zh) * 2010-06-17 2013-06-26 江苏迈迪基因生物科技有限公司 淋巴瘤相关的融合基因的诊断试剂盒
KR101264810B1 (ko) * 2010-11-25 2013-05-15 한국과학기술연구원 Ａｌｋ 유전자의 재배열 검출방법 및 이를 이용한 암 진단방법
CA2823337C (en) 2010-12-29 2019-09-10 Expression Pathology, Inc. Her3 protein srm/mrm assay
CN102719525B (zh) * 2012-04-12 2014-06-04 厦门艾德生物医药科技有限公司 用于检测eml4-alk融合基因突变的引物、探针及检测试剂盒
US9084456B1 (en) * 2012-05-28 2015-07-21 Jack Zemer Linkage for jewelry components
WO2014146139A2 (en) * 2013-03-15 2014-09-18 Expression Pathology, Inc. Srm assay to indicate cancer therapy
EP2986736B1 (en) * 2013-04-17 2019-09-18 Life Technologies Corporation Gene fusions and gene variants associated with cancer
US10072298B2 (en) 2013-04-17 2018-09-11 Life Technologies Corporation Gene fusions and gene variants associated with cancer
CN106414768B (zh) * 2014-03-27 2020-05-29 生命技术公司 与癌症相关的基因融合体和基因变异体
US10597725B2 (en) 2014-09-01 2020-03-24 Arkray, Inc. Primer reagent for amplifying ALK fusion gene, ALK fusion gene amplification reagent kit including the same, and ALK fusion gene amplification method and ALK fusion gene analysis method using the same
JP6533128B2 (ja) * 2014-09-01 2019-06-19 アークレイ株式会社 Ａｌｋ融合遺伝子を増幅するためのプライマー試薬、それを含むａｌｋ融合遺伝子の増幅試薬キット、それを用いたａｌｋ融合遺伝子の増幅方法および分析方法
WO2016106701A1 (zh) * 2014-12-31 2016-07-07 深圳华大基因股份有限公司 检测非小细胞肺癌的qRT-PCR引物、探针、芯片、试剂盒、应用和方法
CN105254764A (zh) * 2015-08-27 2016-01-20 上海康岱生物医药技术有限公司 ACVR1-Fc融合蛋白及其制法和用途
WO2017153932A1 (en) 2016-03-10 2017-09-14 Novartis Ag Strn-alk fusion as a therapeutic target in gastric cancer
WO2017175111A1 (en) 2016-04-04 2017-10-12 Novartis Ag Strn-alk fusion as a therapeutic target in colorectal cancer
JP2020521440A (ja) * 2017-05-31 2020-07-27 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｌｋ、ｒｅｔ、およびｒｏｓ融合の多重ｐｃｒ検出
KR101987065B1 (ko) 2017-08-07 2019-06-10 주식회사 싸이토젠 Eml4-alk유전자 변이 분석방법
KR102182850B1 (ko) * 2018-11-19 2020-11-25 경북대학교 산학협력단 Tfg 나노 입자 또는 tfmg 나노 입자를 포함하는 암 치료용 또는 암 전이 억제용 조성물
JP7385191B2 (ja) 2019-08-30 2023-11-22 学校法人同志社 Ｅｍｌ４－ａｌｋ阻害ペプチドおよびこれを含む肺がん治療薬
CN112794914B (zh) * 2019-11-14 2022-09-16 深圳华大生命科学研究院 一种基于噬菌体展示技术开发的alk纳米抗体及其应用
CN113130001B (zh) * 2021-03-31 2023-07-18 甘肃中医药大学 一种天然化合物与抗肿瘤化合物配伍的筛选方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5529925A (en) * 1993-12-03 1996-06-25 St. Jude Children's Research Hospital Nucleic acid sequences and fusion proteins present in human t(2;5) lymphoma
US7300753B2 (en) * 1998-09-04 2007-11-27 John Rush Immunoaffinity isolation of modified peptides from complex mixtures
US20030099974A1 (en) * 2001-07-18 2003-05-29 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kits and methods for identification, assessment, prevention, and therapy of breast cancer
AU2003262386A1 (en) * 2002-04-17 2003-11-03 Michael R. Blaese Short fragment homologous replacement to provide bse resistant cattle
CA2538413A1 (en) * 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
EP2418281B1 (en) * 2003-10-24 2016-06-01 Gencia Corporation Methods and compositions for delivering polynucleotides
CA2598893C (en) * 2006-10-11 2012-04-10 Astellas Pharma Inc. Eml4-alk fusion gene
EP1914240B1 (en) * 2006-10-11 2009-12-02 Astellas Pharma Inc. EML4-ALK fusion gene

Also Published As

Publication number Publication date
CA2648864A1 (en) 2008-10-23
CA2982018A1 (en) 2008-10-23
CA2982018C (en) 2023-10-17
KR20130004522A (ko) 2013-01-10
CN101466721A (zh) 2009-06-24
CN112057625A (zh) 2020-12-11
CN101466721B (zh) 2013-08-21
JP2010501175A (ja) 2010-01-21
KR20110117734A (ko) 2011-10-27
EP2016089B1 (en) 2014-01-15
WO2008127248A1 (en) 2008-10-23
EP2016089A4 (en) 2009-10-21
KR101274092B1 (ko) 2013-06-25
AU2007351581B2 (en) 2011-12-01
EP2016089A1 (en) 2009-01-21
CA2648864C (en) 2017-11-21
KR101362284B1 (ko) 2014-02-12
ES2458497T3 (es) 2014-05-05
AU2007351581A1 (en) 2008-10-23
JP5562640B2 (ja) 2014-07-30
KR20100005180A (ko) 2010-01-14
HK1122040A1 (en) 2009-05-08

Similar Documents

Publication Publication Date Title
DK2016089T3 (da) Gendefekter og mutant-alk-kinase i humane faste tumorer
DK3401327T3 (da) Genprodukter med forskellig ekspression i tumorer og anvendelser deraf
DK1844074T3 (da) Humane antistoffer og proteiner
DK2287195T3 (da) Pan-kir2dl nk-receptor-antistoffer og anvendelse heraf i diagnostik og terapi
DK3067064T3 (da) Modificerede rsv-f-proteiner og fremgangsmåder til anvendelse deraf
DK1951885T3 (da) Fructooligosaccharidfremstilling in situ og saccharosereduktion
DK2118140T3 (da) Humancytomegalovirus-neutraliserende antistoffer og anvendelse deraf
DK1984344T3 (da) Multicykliske aminosyrederivater og fremgangsmåder til anvendelse heraf
DK2268317T3 (da) Integrin-targeteringssubstanser og in vivo- og in vitro-billeddannelsesmetoder som anvender samme
DK2252633T3 (da) Anti-TrkA antistoffer og derivater deraf
DK3028565T3 (da) Dyremodeller og terapeutiske molekyler
DK1933810T3 (da) Intravesikal lægemiddelafgivelsesindretning og fremgangsmåde
DK2185164T3 (da) Sammensætning og terapeutisk antitumorvaccine
DK1969391T3 (da) Tyndfilm emitter-absorber indretning og fremgangsmåde
DK2179379T3 (da) Terapiindgivelsessystem med åben opbygning og fremgangsmåde deraf
DK2081955T3 (da) Metastinderivater og anvendelse deraf
EP2170950A4 (en) ANTI-IL-20 ANTIBODIES AND ITS USE IN THE TREATMENT OF INFLAMMATORY DISEASES ASSOCIATED WITH IL-20
EP1957095A4 (en) MODIFIED ANNEXIN PROTEINS AND METHOD FOR THEIR APPLICATION TO ORGAN TRANSPLANTS
EP2323680A4 (en) PROTEINS FOR USE IN THE DIAGNOSIS AND TREATMENT OF INFECTIONS AND DISEASES
DK2190991T3 (da) SDF-1-Bindende nucleinsyrer og anvendelsen deraf
FI20050327A0 (fi) Antennijärjestelmä ja menetelmä antennin yhteydessä sekä antenni
DK1885716T3 (da) Thiazolderivater og anvendelse deraf
DK1863801T3 (da) Benzimidazolderivat og anvendelse deraf
DK1976884T3 (da) Anti-ephrinb2-antistoffer og fremgangsmåder til anvendelse deraf.
EP2012798A4 (en) USE OF INOSITOL-TRIPYROPHOSPHATE IN THE TREATMENT OF TUMORS AND DISEASES